Table 2.
Clinical Presentation and Management of Staphylococcus aureus Bacteremia
| Duration of Bacteremia | P Value | |||
|---|---|---|---|---|
| Short (1–2 d) (n = 555) | Intermediate (3–6 d) (n = 250) | Prolonged (≥7 d) (n = 79) | ||
| Pitt bacteremia score (median, IQR) | 0 (0, 2) | 1 (0, 2) | 1 (0, 2) | .019 |
| ≥2 | 169 (30) | 96 (38) | 31 (39) | .046 |
| ≥4 | 58 (10) | 30 (12) | 12 (15) | .42 |
| ICU stay during SAB | 158 (28) | 89 (36) | 44 (56) | <.0001 |
| Duration of ICU stay (median, IQR), d | 5 (2, 12) | 5 (2, 11) | 11 (4, 22.5) | .028 |
| Need for vasopressors | 72 (13) | 60 (24) | 25 (32) | <.0001 |
| Concurrent infections | 127 (23) | 50 (20) | 26 (33) | .064 |
| ID consultation | 278 (50) | 165 (66) | 70 (89) | <.0001 |
| Time to receipt of ID consult from SAB onset (median, IQR), d | 2 (1, 4) | 2 (1, 4) | 3 (2, 6) | .0005 |
| Procedure performed for source control | 245 (44) | 109 (44) | 44 (56) | .13 |
| Incision and drainage | 123 (50) | 42 (38) | 23 (52) | .099 |
| Catheter removal | 94 (38) | 54 (50) | 15 (34) | .088 |
| Time to source-control procedure (median, IQR), d | 1 (1, 3) | 3 (1, 5) | 3.5 (2, 9.75) | <.0001 |
| Initial active antibiotic therapy | .85 | |||
| Vancomycin monotherapy | 170 (31) | 76 (30) | 30 (38) | |
| Vancomycin and β-lactam | 273 (49) | 118 (47) | 35 (44) | |
| Antistaphylococcal β-lactam | 21(4) | 12 (5) | 3 (4) | |
| Other | 91 (16) | 44 (18) | 11 (14) | |
| Time to start active antibiotic therapy | .66 | |||
| Prior to SAB onset | 51 (9) | 18 (7) | 4 (5) | |
| On day of SAB onset | 355 (64) | 159 (64) | 47 (59) | |
| 1-day delay from onset of SAB | 131 (24) | 65 (26) | 25 (32) | |
| 2-day delay from onset of SAB | 18 (3) | 8 (3) | 3 (4) |
Data are no. (%) unless otherwise indicated.
Abbreviations: ICU, intensive care unit; ID, infectious diseases; IQR, interquartile range; SAB, Staphylococcus aureus bacteremia.